Biotechnology - Genomic and Proteomics/Open Business models in BGP: Difference between revisions

From Commons Based Research

< Biotechnology - Genomic and Proteomics

Jump to navigation Jump to search

Revision as of 17:29, 21 April 2009

Report April 2009

Answer

TDI “A kernel for the Tropical Disease Initiative”, Leticia Ort’ et. al., Nature Publishing Group,
- Problem it aims to address: open source drug development has not been successful because there lacks a critical mass of publicly available data. Focus on tropical diseases
- Methodology: develop computational pipeline (e.g. open source data sets) for developing the following: structure modeling of target proteins
- predictions of ligant bonding locations: (e.g., http://www.thesynapticleap.org/), public-private partnerships (e.g., http://www.mmv.org/) and private foundations (e.g., http://www.gatesfoundation.org/);
- predict structures of protein sequences
- products created from using the software do not seem to be required to be put in the public domain
- Uses Science Commons protocol for implementing Open Access Data ((http://sciencecommons.org/projects/publishing/open-access-dataprotocol/)
- Open Source Biotechnology Project, Open source biotechnology?, http://rsss.anu.edu.au/~janeth/OSBiotech.html

Navigation

Bibliography for Item 12 in BGP
Biotechnology_-_Genomic_and_Proteomics

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics/Open_Business_models_in_BGP&oldid=1808"